• AbbVie won European Commission clearance for Rinvoq (upadacitinib) 15 mg once daily for non-segmental vitiligo in patients aged 12+.
• Rinvoq becomes the EU’s first systemic treatment for the condition, expanding its dermatology franchise into a new indication.
• Approval was backed by Phase 3 Viti-Up data showing significant facial and total-body repigmentation at week 48 versus placebo.
• The drug remains under U.S. FDA review for non-segmental vitiligo.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607290300PR_NEWS_USPR_____CG14449) on July 29, 2026, and is solely responsible for the information contained therein.